Alkermes plc (NASDAQ:ALKS) Shares Purchased by AMG National Trust Bank

AMG National Trust Bank boosted its position in shares of Alkermes plc (NASDAQ:ALKS - Free Report) by 68.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 59,645 shares of the company's stock after acquiring an additional 24,200 shares during the period. AMG National Trust Bank's holdings in Alkermes were worth $1,669,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ALKS. Price T Rowe Associates Inc. MD boosted its holdings in shares of Alkermes by 421.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 8,326,256 shares of the company's stock valued at $225,393,000 after acquiring an additional 6,730,671 shares during the period. Armistice Capital LLC raised its stake in shares of Alkermes by 301.5% during the 2nd quarter. Armistice Capital LLC now owns 2,699,179 shares of the company's stock worth $65,050,000 after buying an additional 2,026,961 shares in the last quarter. Pacer Advisors Inc. lifted its holdings in Alkermes by 31.8% in the second quarter. Pacer Advisors Inc. now owns 5,640,642 shares of the company's stock valued at $135,939,000 after acquiring an additional 1,362,079 shares during the period. American Century Companies Inc. boosted its position in shares of Alkermes by 87.1% during the 2nd quarter. American Century Companies Inc. now owns 2,203,456 shares of the company's stock worth $53,103,000 after purchasing an additional 1,025,905 shares in the last quarter. Finally, Affinity Asset Advisors LLC grew its stake in shares of Alkermes by 766.7% during the 2nd quarter. Affinity Asset Advisors LLC now owns 650,000 shares of the company's stock worth $15,665,000 after purchasing an additional 575,000 shares during the period. Institutional investors and hedge funds own 95.21% of the company's stock.

Insider Buying and Selling at Alkermes

In other Alkermes news, EVP Craig C. Hopkinson sold 10,471 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $29.53, for a total transaction of $309,208.63. Following the transaction, the executive vice president now owns 99,238 shares of the company's stock, valued at $2,930,498.14. This trade represents a 9.54 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 4.89% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Robert W. Baird upped their target price on shares of Alkermes from $37.00 to $38.00 and gave the stock an "outperform" rating in a research report on Thursday, July 25th. The Goldman Sachs Group dropped their price objective on Alkermes from $32.00 to $30.00 and set a "buy" rating for the company in a research note on Friday, October 25th. JPMorgan Chase & Co. lowered their target price on Alkermes from $32.00 to $26.00 and set a "neutral" rating on the stock in a report on Friday, October 25th. StockNews.com upgraded Alkermes from a "hold" rating to a "buy" rating in a research report on Sunday, July 28th. Finally, HC Wainwright reiterated a "neutral" rating and set a $37.00 price target on shares of Alkermes in a report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $35.42.

Alkermes Stock Up 0.3 %

NASDAQ:ALKS traded up $0.09 during mid-day trading on Tuesday, hitting $27.64. The company had a trading volume of 712,533 shares, compared to its average volume of 1,826,170. Alkermes plc has a 1 year low of $22.22 and a 1 year high of $32.88. The business has a fifty day simple moving average of $27.80 and a 200-day simple moving average of $26.27. The company has a current ratio of 3.45, a quick ratio of 3.03 and a debt-to-equity ratio of 0.22. The firm has a market capitalization of $4.47 billion, a price-to-earnings ratio of 14.13, a PEG ratio of 0.94 and a beta of 0.47.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.